Business News: Incyte Buys Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
Incyte has acquired Escient Pharmaceuticals and its pipeline of first-in-class oral MRGPR antagonists, including EP262, a once-daily small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2) and EP547, an oral MRGPRX4 antagonist. “As a company dedicated to innovation and the discovery of transformative medicines, we are excited to add EP262 and EP547 to […]